4.6 Article

Inhibition of p73 function by Pifithrin-α as revealed by studies in zebrafish embryos

期刊

CELL CYCLE
卷 7, 期 9, 页码 1224-1230

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/cc.7.9.5786

关键词

zebrafish; development; radiation effects; tumor suppressor protein p53; tumor suppressor protein p73; pifithrin-alpha

资金

  1. NCI NIH HHS [CA81008, CA10663, CA119951, P30-CA56036] Funding Source: Medline

向作者/读者索取更多资源

The p53 family of proteins contains two members that have been implicated in sensitization of cells and organisms to genotoxic stress, i.e., p53 itself and p73. In vitro, lack of either p53 or p73 can protect certain cell types in the adult organism against death upon exposure to DNA damaging agents. The present study was designed to assess the relative contribution of p53 to radiation resistance of an emerging vertebrate model organism, i.e., zebrafish embryos. Consistent with previous reports, suppressing p53 protein expression using antisense morpholino oligonucleotides (MOs) increased survival and reduced gross morphological alterations in zebrafish embryos exposed to ionizing radiation. By contrast, a pharmacological inhibitor of p53 function [Pifithrin-alpha (PFT alpha)] caused developmental abnormalities affecting the head, brain, eyes and kidney function and did not protect against lethal effects of ionizing radiation when administered at 3 hours post fertilization (hpf). The phenotypic abnormalities associated with PFTa treatment were similar to those caused by antisense MO knock down (kd) used to reduce p73 expression. PFT alpha also inhibited p73-dependent transcription of a reporter gene construct containing canonical p53-responsive promoter sequences. Notably, when administered at later stages of development (23 hpf), PFT alpha did not cause overt developmental defects but exerted radioprotective effects in zebrafish embryos. In summary, this study highlights off-target effects of the pharmacological p53 inhibitor PFT alpha related to inhibition of p73 function and essential roles of p73 at early but not later stages of zebrafish development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features Comparative Analysis of Long-term Outcomes

Mark V. Mishra, Eli D. Scher, Jocelyn Andrel, Andrew C. Margules, Sarah E. Hegarty, Edouard J. Trabulsi, Terry Hyslop, Robert B. Den, Costas D. Lallas, Leonard G. Gomella, Adam P. Dicker, Timothy N. Showalter

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)

Article Oncology

Quantifying Unnecessary Normal Tissue Complication Risks due to Suboptimal Planning: A Secondary Study of RTOG 0126

Kevin L. Moore, Rachel Schmidt, Vitali Moiseenko, Lindsey A. Olsen, Jun Tan, Ying Xiao, James Galvin, Stephanie Pugh, Michael J. Seider, Adam P. Dicker, Walter Bosch, Jeff Michalski, Sasa Mutic

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)

Article Oncology

Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy

Robert B. Den, Kasra Yousefi, Edouard J. Trabulsi, Firas Abdollah, Voleak Choeurng, Felix Y. Feng, Adam P. Dicker, Costas D. Lallas, Leonard G. Gomella, Elai Davicioni, R. Jeffrey Karnes

JOURNAL OF CLINICAL ONCOLOGY (2015)

Article Oncology

American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment

Jeffrey S. Weber, Laura A. Levit, Peter C. Adamson, Suanna Bruinooge, Howard A. Burris, Michael A. Carducci, Adam P. Dicker, Mithat Goenen, Stephen M. Keefe, Michael A. Postow, Michael A. Thompson, David M. Waterhouse, Susan L. Weiner, Lynn M. Schuchter

JOURNAL OF CLINICAL ONCOLOGY (2015)

Article Oncology

Current Clinical Trials Testing Combinations of Immunotherapy and Radiation

Mario Crittenden, Holbrook Kohrt, Ronald Levy, Jennifer Jones, Kevin Camphausen, Adam Dicker, Sandra Demaria, Silvia Formenti

SEMINARS IN RADIATION ONCOLOGY (2015)

Article Oncology

African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men

Kosj Yamoah, Curtiland Deville, Neha Vapiwala, Elaine Spangler, Charnita M. Zeigler-Johnson, Bruce Malkowicz, David I. Lee, Michael Kattan, Adam P. Dicker, Timothy R. Rebbeck

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)

Review Engineering, Biomedical

Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data

Nicholas George Zaorsky, Mark D. Hurwitz, Adam P. Dicker, Timothy N. Showalter, Robert B. Den

EXPERT REVIEW OF MEDICAL DEVICES (2015)

Article Multidisciplinary Sciences

Evaluating the Clinical Impact of a Genomic Classifier in Prostate Cancer Using Individualized Decision Analysis

Jennifer Mason Lobo, Adam P. Dicker, Christine Buerki, Elai Daviconi, R. Jeffrey Karnes, Robert B. Jenkins, Nirav Patel, Robert B. Den, Timothy N. Showalter

PLOS ONE (2015)

Article Health Care Sciences & Services

Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial

Christine Tran, Adam Dicker, Benjamin Leiby, Eric Gressen, Noelle Williams, Heather Jim

JOURNAL OF MEDICAL INTERNET RESEARCH (2020)

Article Oncology

Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors

Heather S. L. Jim, Sarah L. Eisel, Aasha Hoogland, Sandra Shaw, Jennifer C. King, Adam P. Dicker

Summary: Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but few studies have evaluated patient-reported outcomes (PROs) outside clinical trials. This study assessed PROs in lung cancer registry participants treated with ICIs, revealing worse quality of life and higher rates of adverse events than previously reported.

CANCERS (2021)

Review Oncology

Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health

Rahul Banerjee, Nina Shah, Adam P. Dicker

Summary: CAR-T therapy is a paradigm-shifting immunotherapy in oncology, but unique toxicities limit its wider implementation. Digital innovations may improve toxicity monitoring, management, and supportive care. Applying digital tools to CAR-T therapy implementation could enhance its safety and accessibility.

JCO CLINICAL CANCER INFORMATICS (2021)

Article Oncology

A Pilot Feasibility Study of Digital Health Coaching for Men With Prostate Cancer

Nathan R. Handley, Kuang-Yi Wen, Sameh Gomaa, Kelly Brassil, Ayako Shimada, Benjamin Leiby, Lindsey Jackson, Michael McMorris, Anne Calvaresi, Adam P. Dicker

Summary: Digital health coaching for men with prostate cancer is feasible, supporting further evaluation in larger randomized controlled trials.

JCO ONCOLOGY PRACTICE (2022)

Article Oncology

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma

Christina I. Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, Martha M. Matuszak, Enrico C. Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John T. Hamm, Kevin S. Oh, Arif N. Ali, Michelle M. Kim, Scott M. Lindhorst, Minesh P. Mehta

Summary: This study evaluated whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS) compared to BEV alone in recurrent glioblastoma (GBM). The results showed that the combination of re-RT and BEV significantly improved PFS, but had no difference in OS.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC

Joanne B. Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A. Bogart, Yolanda I. Garces, Samir Narayan, Clifford G. Robinson, Vivek S. Kavadi, Joel S. Greenberger, Christopher D. Koprowski, James Welsh, Elizabeth M. Gore, Robert M. Macrae, Rebecca Paulus, Jeffrey D. Bradley

Summary: Although overall survival advantage was not observed in KRAS-variant patients, there is a potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy.

CANCER RESEARCH COMMUNICATIONS (2023)

暂无数据